Literature DB >> 18022065

Impact of a severe influenza vaccine shortage on primary care practice.

Allison Kempe1, Matthew F Daley, Shannon Stokley, Lori A Crane, Brenda L Beaty, Jennifer Barrow, Christine Babbel, L Miriam Dickinson, John F Steiner, Stephen Berman.   

Abstract

BACKGROUND: Because of influenza vaccine shortages during the 2004-2005 influenza season, vaccine was targeted for high-risk priority groups.
OBJECTIVES: To assess among primary care physicians: (1) ability to identify priority patients; (2) extent of shortages; and (3) effects of shortages on vaccine redistribution, patient referral and future plans for vaccine delivery.
METHODS: Mailed surveys of pediatric (Peds), family medicine (FM), and general internal medicine (GIM) physicians randomly selected from the American Medical Association master file.
RESULTS: Response rate was 37% and the study population included 377 Peds, 319 FM, and 251 GIM physicians. Seventy-five percent of Peds, 58% of FM and 60% of GIM had some method to identify priority patients, although only 39%, 21%, and 18%, respectively, had a computerized method. Forty-five percent of Peds, 73% of FM, and 75% of GIM experienced shortages, for a median of 2-3 months. Approximately 48%-50% of Peds, FM, and GIM obtained additional influenza doses; among these, 53% received vaccine from a public health entity. Fifty-one percent of Peds, 79% of FM, and 80% of GIM referred high-risk patients for immunization, 94% of the time to a public health clinic. More than 95% planned to administer influenza vaccine next season.
CONCLUSIONS: The majority of physicians experienced influenza vaccine shortages for prioritized patients, especially those providers caring for adults. There was significant vaccine redistribution and patient referral, primarily involving the public health system. Enhancing methods of targeting priority patients and increasing cooperation with public health entities should be priorities in dealing with future influenza vaccine shortages.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022065     DOI: 10.1016/j.amepre.2007.07.038

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  10 in total

1.  A Blueprint for Improving the Promotion and Delivery of Adult Vaccination in the United States.

Authors:  Katherine M Harris; Lori Uscher-Pines; Soeren Mattke; Arthur L Kellermann
Journal:  Rand Health Q       Date:  2012-03-01

2.  Dose sparing and the lack of a dose-response relationship with an influenza vaccine in adult and elderly patients - a randomized, double-blind clinical trial.

Authors:  Zoltan Vajo; Gergely Balaton; Peter Vajo; Laszlo Kalabay; Adam Erdman; Peter Torzsa
Journal:  Br J Clin Pharmacol       Date:  2017-04-11       Impact factor: 4.335

3.  Practice and child characteristics associated with influenza vaccine uptake in young children.

Authors:  Katherine A Poehling; Gerry Fairbrother; Yuwei Zhu; Stephanie Donauer; Sandra Ambrose; Kathryn M Edwards; Mary Allen Staat; Mila M Prill; Lyn Finelli; Norma J Allred; Barbara Bardenheier; Peter G Szilagyi
Journal:  Pediatrics       Date:  2010-09-06       Impact factor: 7.124

4.  The benefits to all of ensuring equal and timely access to influenza vaccines in poor communities.

Authors:  Bruce Y Lee; Shawn T Brown; Rachel R Bailey; Richard K Zimmerman; Margaret A Potter; Sarah M McGlone; Philip C Cooley; John J Grefenstette; Shanta M Zimmer; William D Wheaton; Sandra Crouse Quinn; Ronald E Voorhees; Donald S Burke
Journal:  Health Aff (Millwood)       Date:  2011-06       Impact factor: 6.301

5.  The impact of missed opportunities on seasonal influenza vaccination coverage for healthy young children.

Authors:  Norma J Allred; Katherine A Poehling; Peter G Szilagyi; Fan Zhang; Kathryn M Edwards; Mary Allen Staat; Stephanie Donauer; Mila M Prill; Gerry Fairbrother
Journal:  J Public Health Manag Pract       Date:  2011 Nov-Dec

6.  Distributing Publicly-Funded Influenza Vaccine-Community Pharmacies' Perspectives on Acquiring Vaccines from Public Health and from Private Distributors in Ontario, Canada.

Authors:  Joseph Fonseca; Richard Violette; Sherilyn K D Houle; Nancy M Waite
Journal:  Pharmacy (Basel)       Date:  2021-04-24

Review 7.  Assessing the Importance of Domestic Vaccine Manufacturing Centers: An Overview of Immunization Programs, Vaccine Manufacture, and Distribution.

Authors:  Emma Rey-Jurado; Felipe Tapia; Natalia Muñoz-Durango; Margarita K Lay; Leandro J Carreño; Claudia A Riedel; Susan M Bueno; Yvonne Genzel; Alexis M Kalergis
Journal:  Front Immunol       Date:  2018-01-18       Impact factor: 7.561

8.  Extinction of the Influenza B Yamagata Line during the COVID Pandemic-Implications for Vaccine Composition.

Authors:  Zoltan Vajo; Peter Torzsa
Journal:  Viruses       Date:  2022-08-09       Impact factor: 5.818

Review 9.  A Review of DNA Vaccines Against Influenza.

Authors:  Leo Yi Yang Lee; Leonard Izzard; Aeron C Hurt
Journal:  Front Immunol       Date:  2018-07-09       Impact factor: 7.561

10.  A Reduced Dose Whole Virion Aluminum Adjuvanted Seasonal Influenza Vaccine Is Immunogenic, Safe, and Well Tolerated in Pediatric Patients.

Authors:  Zoltan Vajo; Gergely Balaton; Peter Vajo; Peter Torzsa
Journal:  Viruses       Date:  2021-03-18       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.